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To the Editor: 
Pediatric pulmonary arterial hypertension (PAH) is a rare and lethal disease. Although the 
availability of PAH-targeted drugs has improved the outcome of these patients, there is still a 
high need for optimization of treatment strategies. In this context, accurate risk stratification 
of patients with PAH is regarded crucial. During the World Symposium on Pulmonary 
Hypertension in 2013 (WSPH 2013) a pediatric task force proposed a risk stratification tool 
for children with PAH that stratifies children into a lower or higher risk group for mortality.
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This model, that was then included in the guidelines for pediatric PAH from the American 
Heart Association and American Thoracic Society,
2
 consists of variables that were selected 
based on either expert opinion or reported prognostic value. Although the prognostic values of 
several of these pediatric risk factors have been studied individually,
3
  their combination in a 
pediatric PAH risk model and its potential use in goal-oriented treatment strategies have not 
been investigated before. We investigated the prognostic value of this pediatric PAH risk 
stratification tool, both at time of diagnosis and at one-year-follow-up. We also examined the 
applicability and potential clinical value of a low-risk profile as treatment target.  
Children (≤18 years old with idiopathic or hereditary PAH (IPAH/HPAH)) consecutively 
enrolled in the prospective clinical registry of the National Referral Center for Pediatric 
Pulmonary Hypertension in the Netherlands between 1993 and 2017 were included in the 
study. All patients had a standardized diagnostic work-up at presentation and were followed 
prospectively using a standardized protocol. Ethical approval for this ongoing registry was 
obtained from the Medical Ethics Review Board of the University Medical Center Groningen 
and written informed consent, from the patients and/or their guardians, was given at 
enrollment. Diagnosis of PAH was confirmed with right heart catheterization (RHC) or in 
case of clinical instability with echocardiography (n=4). For this study we assessed two 
versions of the risk stratification model based on the number of low-risk criteria. First, we 
tested the full model proposed at the WSPH 2013, augmented with two extra variables, 
systemic venous oxygen saturation (SvO2) and right atrial area (RA-area), extracted from the 
2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines 
and proven to be prognostic for outcome also in pediatric PAH.
4–8
 This resulted in a total of 
13 low-risk criteria: absence of syncope, height z-score >-2, body mass index (BMI) z-score 
>-2, World Health Organization Functional Class (WHO-FC) I/II, N-terminal pro-B-Type 
Natriuretic Peptide (NT-proBNP) ≤1200 ng/l, tricuspid plane systolic excursion (TAPSE) ≥12 
mm, RA-area <18 cm², systemic cardiac index ≥2.5 l/min/m², ratio of mean pulmonary 
arterial pressure over mean systemic arterial pressure (mPAP/mSAP) <0.75, mean right atrial 
pressure (mRAP) ≤10 mmHg, pulmonary vascular resistance index (PVRi) ≤ 20 WU∙m², 
acute responder at vasoreactivity testing according to Sitbon criteria, and SvO2 >65%. This 
full model was tested at time of diagnosis only, since invasive hemodynamic data at one-year 
follow-up were not collected per protocol and absent in the majority of patients. Next, a 
model restricted to non-invasive low-risk criteria (excluding hemodynamics and thus yielding 
7 low-risk criteria) was tested both at time of diagnosis and at one-year follow-up within a 
time-window of six months before and after. Analyses were performed on the original dataset 
and also after imputation of missing values. Multiple imputation with fully conditional 
specification (IBM SPSS) was used to impute missing values for variables with <50% 
missing data which met the ‘missing at random’ assumption, both at diagnosis and at follow-
up.
9
 Pooled analyses were performed on 15 imputed datasets, generated using multiple 
imputation with 20 iterations. For each dataset the number of low-risk criteria per patient was 
calculated and all the 15 datasets were combined and pooled analysis yielded an average of 
the total number of low-risk criteria for every patient. Transplant-free survival was the 
primary outcome variable. Survival according to the number of low-risk criteria at diagnosis 
and at one-year-follow-up in both the models was assessed with the Kaplan-Meier method, 
compared using the log-rank test. Time-dependent receiver operating characteristics analysis 
of the number of low-risk factors at time of diagnosis according to both the full WSPH 2013 
model and the non-invasive model were analyzed with the TimeROC package in R.
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58 children (53.4% female) with IPAH/HPAH were included for analyses at time of 
diagnosis. The median (IQR) age was 6.8 (2.2-13.4) years. The median (IQR) follow-up 
duration was 3.1 (0.7-8.4) years. At diagnosis more patients were in WHO-FC III (39.7%) or 
IV (27.6%) than in WHO-FC I-II (32.7%). Figure 1A shows that, using the full WSPH 2013 
model, patients with a higher number of low-risk factors had significantly better transplant-
free survival (log-rank test p=0.001). Time-dependent receiver operating characteristics 
(ROC) analysis of the full model for survival status at 5 year follow-up yielded an area under 
the curve (AUC) of 0.78 (SE 0.07). The optimal threshold value (on a continuous scale of 0-
13 low-risk factors) when maximizing sensitivity and negative predictive value was estimated 
at 10 low-risk factors. Sensitivity: 0.96 (SE 0.04), specificity: 0.46 (SE 0.10), positive 
predictive value (PPV):  0.57 (SE 0.08), negative predictive value (NPV): 0.93 (SE 0.06). A 
calibration plot comparing the observed and expected survival for the full WSPH 2013 model 
showed a good goodness of fit.  Using the non-invasive model, children who had all seven 
low-risk criteria at time of diagnosis, showed 1-, 3- and 5-year survival rates of 100%. In 
contrast, patients with only three non-invasive low-risk criteria showed 1-, 3- and 5-year 
survival rates of 69%, 35% and 35% respectively. The higher the number of low-risk criteria 
present at diagnosis, the better was transplant-free survival (log-rank test p=0.009). Time-
dependent ROC analysis of the non-invasive model at 5 year follow-up yielded an AUC of 
0.76 (SE 0.07). The optimal threshold value (on a continuous scale of 0-7 non-invasive low-
risk factors) when maximizing specificity and PPV was estimated at 4 low-risk factors. 
Sensitivity: 0.52 (SE 0.11), specificity: 0.83 (SE 0.08), PPV: 0.71 (SE 0.12), NPV: 0.70 (SE 
0.08). When setting the threshold value at 5 low-risk factors (which was used in our change 
model, Figure 1B) the values are: sensitivity: 0.74 (SE 0.09), specificity: 0.75 (SE 09), PPV: 
0.69 (SE 0.10), NPV: 0.79 (SE 0.08). At 1 year follow-up ( median 12.5 months; IQR 10.9-
13.5), non-invasive measurements were performed in 44 children. Children with 7 non-
invasive low-risk criteria at one-year-follow-up had 1-, 3- and 5-year survival rates of 100%, 
86% and 86%, whereas those with only 3 low-risk criteria: 33%, 33% and 33% respectively. 
The higher the number of low-risk criteria present at follow-up, the better was transplant-free 
survival (log-rank test p=0.009). Children who presented with ≥ 5 out of 7 non-invasive low-
risk criteria at diagnosis and retained these at one-year-follow-up had a better prognosis than 
those who at re-evaluation retained only ≤ 4 low-risk criteria, independent which low-risk 
criteria were maintained (p=0.003)(Figure 1B). A calibration plot comparing the observed and 
expected survival for the different change groups showed a good goodness of fit. Importantly, 
the limited number of study patients did not allow analysis of the individual contribution of 
each low-risk component and therefore the low-risk components were not weighed. Children 
who had ≤ 4 low-risk criteria at diagnosis but improved towards ≥ 5 low-risk variables at the 
time of re-evaluation had a better transplant-free survival compared to those who maintained 
having ≤ 4 low-risk criteria at follow-up. 
These findings in a national cohort of children with PAH are in line with those in a 
French national cohort of adults with PAH. Boucly et al. found that risk assessment both at 
diagnosis and at first re-evaluation, using criteria proposed in the 2015 ESC/ERS guidelines 
for adults with PAH, accurately predicted prognosis.
11
 In the current study, time-dependent 
ROC analyses yielded AUCs of >0.7 for both the full WSPH 2013 and the non-invasive 
model, indicating fair models. The full model was especially accurate in identifying those 
patients who were at lower risk for mortality. Patients with 10 or more low-risk factors had 
better survival than patients with less than 10 low-risk factors. This can be used for clinicians 
when treating children with PAH. From the non-invasive model, the results of sensitivity, 
specificity, PPV and NPV were not optimal, which means that this model needs optimization. 
Our results further suggest that preserving or reaching a low-risk profile at follow-up may be 
valuable as a treatment goal in pediatric PAH. However, it is important to keep in mind that 
the observed association between a change in number of low-risk criteria and outcome not 




The sample size in the current study is relatively small for testing predictive models 
with multiple variables, limiting statistical power and confidence. Also, the tested models do 
not have an optimal discriminative power. Improving the discriminative power of both models 
could be reached with using weighing factors, increasing the contribution of more sensitive 
variables (from univariable Cox regression analysis) with a weighing system.
13,14
 Validation 
of the current findings in a separate cohort of children with PAH is necessary.  
This study suggests that both the full WSPH 2013 pediatric risk stratification tool and a 
simplified, non-invasive pediatric risk model indeed predicted outcome in children with 
IPAH/HPAH. Also, preserving or reaching a low-risk profile at follow-up, was associated 
with improved survival and may thus serve as a treatment goal in pediatric PAH.  
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Figure 1 (A) Transplant-free survival according to the full WSPH 2013 pediatric risk 
stratification model, (B) transplant-free survival according to the change in number of low-
risk criteria between baseline and one-year-follow-up for the non-invasive model. 
 
 
 
 
 
 
 
 
 
 
 
 
